ADA and severe combined immunodeficiency: Since 1990, when the first gene therapy trial was performed in two children with adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID) (6), this approach has been studied for and applied to a variety of inherited and acquired disorders, with more than 20 gene therapies officially approved for clinical uses by the drug regulatory agencies from different countries.